Company profile: Biosyntia
1.1 - Company Overview
Company description
- Provider of synthetic biology and metabolic engineering solutions, developing biocatalysts and tailored biocatalysis processes using patent-pending high-throughput screening. Offers BIO-B7 natural biotin (high-purity, traceable), Eraglow skincare actives based on fermented biotin, and Forskeffect botanical forskolin. Provides Biosynthetic Selections for ultra-high-throughput testing of engineered microorganisms and partnering on fermentation process development.
Products and services
- Biosynthetic Selections™: Engineers a suite of synthetic-biology technologies enabling ultra-high-throughput testing of engineered microorganisms for compound productivity via patent-pending high-throughput screening technology
- Ultra-high-throughput
- BIO-B7™: Produces natural biotin (vitamin B7) through fermentation of beet carbohydrate complexes by microorganisms, delivering high purity and traceability as a fermentation-based ingredient
- Fermentation-derived
- Partnering: Collaboratively architects tailored biocatalysis-based fermentation processes with companies, emphasizing value-sharing and leveraging synergies across ingredient programs to accelerate development
- Custom-engineered
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Biosyntia
Visikol
HQ: United States
Website
- Description: Provider of CRO services focused on digital pathology, 3D tissue imaging, and 3D cell culture assays/models. Delivers end-to-end 2D/3D in vitro models, tissue clearing (Visikol HISTO) and confocal microscopy, high content screening, bio-imaging, bioinformatics and image analysis, plus custom drug discovery solutions and 21 CFR Part 11 compliant digital pathology software.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Visikol company profile →
Nanotether Discovery Services
HQ: United Kingdom
Website
- Description: Provider of pharmaceutical research technology developing innovative bio-chip technology, based in Cardiff, UK.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanotether Discovery Services company profile →
Metenova
HQ: Sweden
Website
- Description: Provider of magnetic mixers for the global pharmaceutical and biotech industry.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Metenova company profile →
Nanoplex Technologies
HQ: United States
Website
- Description: Provider of nanoparticle-based products for life science research, enabling ultra-sensitive molecular identification and quantitation, as well as authentication and tracking applications; focused on rapidly translating state-of-the-art nanoscience into practical, valuable products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanoplex Technologies company profile →
Camurus
HQ: Sweden
Website
- Description: Provider of innovative specialty medicines, with research-based development and commercialization aimed at improving treatment outcomes and quality of life for patients with serious and chronic diseases; based in Lund.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Camurus company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Biosyntia
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Biosyntia
2.2 - Growth funds investing in similar companies to Biosyntia
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Biosyntia
4.2 - Public trading comparable groups for Biosyntia
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →